EMA Withdrawn: Dutrebis (lamivudine;raltegravir potassium) — Merck Sharp Dohme Limited

View source ↗

Summary

EMA withdrew Dutrebis (lamivudine and raltegravir potassium) for HIV infections, decision dated 26 March 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Dutrebis (lamivudine; raltegravir potassium)

Snippet

Status: Withdrawn. Therapeutic area: HIV Infections. MAH: Merck Sharp Dohme Limited. Decision date: 26/03/2015